Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 50 | 2016 | 3357 | 4.450 |
Why?
|
| Kidney | 19 | 2016 | 1241 | 3.440 |
Why?
|
| Oxygen | 18 | 2016 | 726 | 3.320 |
Why?
|
| Osteoarthritis, Knee | 9 | 2011 | 63 | 1.620 |
Why?
|
| Contrast Media | 19 | 2016 | 1078 | 1.470 |
Why?
|
| Cartilage, Articular | 10 | 2011 | 67 | 1.280 |
Why?
|
| Kidney Medulla | 7 | 2007 | 80 | 1.210 |
Why?
|
| Gadolinium DTPA | 9 | 2011 | 261 | 1.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2016 | 663 | 1.060 |
Why?
|
| Renal Circulation | 3 | 2014 | 61 | 1.050 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2016 | 262 | 0.980 |
Why?
|
| Furosemide | 7 | 2016 | 33 | 0.960 |
Why?
|
| Kidney Diseases | 5 | 2015 | 418 | 0.940 |
Why?
|
| Nitric Oxide Synthase | 3 | 2011 | 125 | 0.940 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 123 | 0.830 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2010 | 579 | 0.760 |
Why?
|
| NG-Nitroarginine Methyl Ester | 5 | 2016 | 45 | 0.740 |
Why?
|
| Oxygen Consumption | 7 | 2016 | 239 | 0.720 |
Why?
|
| Osteoarthritis | 4 | 2008 | 73 | 0.700 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2016 | 1219 | 0.690 |
Why?
|
| Diuretics | 5 | 2014 | 124 | 0.670 |
Why?
|
| Triiodobenzoic Acids | 4 | 2015 | 10 | 0.640 |
Why?
|
| Rats | 12 | 2016 | 3990 | 0.640 |
Why?
|
| Diabetic Nephropathies | 2 | 2010 | 248 | 0.560 |
Why?
|
| Diuresis | 3 | 2011 | 29 | 0.560 |
Why?
|
| Sensitivity and Specificity | 10 | 2016 | 1991 | 0.520 |
Why?
|
| Manganese | 2 | 2006 | 53 | 0.510 |
Why?
|
| Knee | 2 | 2011 | 16 | 0.480 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 53 | 0.480 |
Why?
|
| Animals | 27 | 2017 | 26582 | 0.470 |
Why?
|
| Renal Artery | 1 | 2014 | 64 | 0.470 |
Why?
|
| Water | 3 | 2011 | 277 | 0.470 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 50 | 0.470 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 152 | 0.460 |
Why?
|
| Oximetry | 2 | 2016 | 84 | 0.460 |
Why?
|
| Male | 36 | 2016 | 40958 | 0.460 |
Why?
|
| Ureteral Obstruction | 1 | 2013 | 67 | 0.450 |
Why?
|
| Knee Joint | 5 | 2011 | 168 | 0.450 |
Why?
|
| Disease Models, Animal | 7 | 2015 | 2232 | 0.440 |
Why?
|
| Hypoxia | 3 | 2017 | 641 | 0.430 |
Why?
|
| Image Enhancement | 3 | 2013 | 563 | 0.430 |
Why?
|
| Nitric Oxide | 2 | 2011 | 278 | 0.430 |
Why?
|
| Dextrans | 1 | 2011 | 77 | 0.400 |
Why?
|
| Glucose | 2 | 2011 | 638 | 0.390 |
Why?
|
| Nitric Oxide Donors | 1 | 2010 | 12 | 0.380 |
Why?
|
| Kidney Tubules | 1 | 2011 | 94 | 0.380 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2010 | 40 | 0.380 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 2705 | 0.380 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 37 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 509 | 0.370 |
Why?
|
| Spin Labels | 3 | 2014 | 102 | 0.300 |
Why?
|
| Artifacts | 3 | 2004 | 244 | 0.300 |
Why?
|
| Whole Body Imaging | 1 | 2007 | 41 | 0.290 |
Why?
|
| Blood Flow Velocity | 4 | 2014 | 197 | 0.290 |
Why?
|
| Free Radical Scavengers | 2 | 2014 | 59 | 0.290 |
Why?
|
| Humans | 39 | 2016 | 86617 | 0.280 |
Why?
|
| Female | 27 | 2017 | 44509 | 0.270 |
Why?
|
| Hypertension | 2 | 2005 | 1141 | 0.260 |
Why?
|
| Liver | 1 | 2010 | 1230 | 0.260 |
Why?
|
| Cyclic N-Oxides | 1 | 2005 | 33 | 0.260 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2004 | 159 | 0.260 |
Why?
|
| Drinking | 1 | 2004 | 34 | 0.250 |
Why?
|
| Bone Malalignment | 3 | 2011 | 7 | 0.250 |
Why?
|
| Magnetite Nanoparticles | 2 | 2016 | 27 | 0.240 |
Why?
|
| Adult | 16 | 2015 | 25640 | 0.230 |
Why?
|
| Phantoms, Imaging | 6 | 2010 | 429 | 0.230 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 376 | 0.220 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 466 | 0.220 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 162 | 0.210 |
Why?
|
| Middle Aged | 17 | 2014 | 25017 | 0.210 |
Why?
|
| Kidney Cortex | 3 | 2007 | 33 | 0.200 |
Why?
|
| Lipocalins | 3 | 2015 | 35 | 0.200 |
Why?
|
| Acute-Phase Proteins | 3 | 2015 | 37 | 0.190 |
Why?
|
| Ions | 2 | 2011 | 74 | 0.190 |
Why?
|
| Heart | 2 | 2003 | 539 | 0.190 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 295 | 0.190 |
Why?
|
| Radiographic Image Enhancement | 1 | 2002 | 462 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 350 | 0.180 |
Why?
|
| Iron | 2 | 2014 | 164 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1804 | 0.170 |
Why?
|
| Ventricular Function, Left | 1 | 2002 | 592 | 0.160 |
Why?
|
| Feasibility Studies | 6 | 2014 | 751 | 0.160 |
Why?
|
| Swine | 3 | 2010 | 555 | 0.160 |
Why?
|
| Reference Values | 3 | 2004 | 674 | 0.160 |
Why?
|
| Aged | 15 | 2014 | 18402 | 0.150 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2017 | 17 | 0.150 |
Why?
|
| Uterine Contraction | 1 | 2017 | 9 | 0.150 |
Why?
|
| Visceral Pain | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hyperalgesia | 1 | 2017 | 16 | 0.150 |
Why?
|
| Platelet Activating Factor | 1 | 2017 | 53 | 0.150 |
Why?
|
| Time Factors | 5 | 2011 | 5209 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 645 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1961 | 0.140 |
Why?
|
| Theranostic Nanomedicine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 115 | 0.140 |
Why?
|
| Mice | 5 | 2017 | 11352 | 0.140 |
Why?
|
| Uterus | 1 | 2017 | 215 | 0.130 |
Why?
|
| Metals | 1 | 2016 | 90 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 3092 | 0.130 |
Why?
|
| Algorithms | 2 | 2014 | 1830 | 0.130 |
Why?
|
| Rats, Inbred SHR | 2 | 2005 | 29 | 0.120 |
Why?
|
| Rats, Inbred WKY | 2 | 2005 | 31 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 69 | 0.120 |
Why?
|
| Acetylcysteine | 1 | 2014 | 69 | 0.120 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 190 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 806 | 0.120 |
Why?
|
| Vasodilation | 1 | 2014 | 96 | 0.120 |
Why?
|
| Vasoconstriction | 1 | 2014 | 93 | 0.120 |
Why?
|
| Ferrosoferric Oxide | 2 | 2011 | 18 | 0.120 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 96 | 0.120 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 203 | 0.110 |
Why?
|
| Tibial Meniscus Injuries | 2 | 2010 | 19 | 0.110 |
Why?
|
| Nephrology | 1 | 2013 | 45 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1019 | 0.110 |
Why?
|
| Macrophages | 1 | 2016 | 554 | 0.110 |
Why?
|
| Viscosity | 1 | 2012 | 46 | 0.110 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 181 | 0.110 |
Why?
|
| Menisci, Tibial | 2 | 2010 | 25 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2006 | 482 | 0.100 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 223 | 0.100 |
Why?
|
| Hippocampus | 1 | 2014 | 442 | 0.100 |
Why?
|
| Nitroimidazoles | 1 | 2010 | 8 | 0.100 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 19 | 0.100 |
Why?
|
| Splanchnic Circulation | 1 | 2010 | 16 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2013 | 839 | 0.100 |
Why?
|
| Swine, Miniature | 1 | 2010 | 51 | 0.100 |
Why?
|
| Lipocalin-2 | 3 | 2015 | 38 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 470 | 0.100 |
Why?
|
| Prostaglandins | 1 | 2010 | 43 | 0.100 |
Why?
|
| Heart Diseases | 2 | 2004 | 290 | 0.100 |
Why?
|
| Naproxen | 1 | 2010 | 13 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2010 | 165 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1621 | 0.090 |
Why?
|
| Knee Injuries | 1 | 2010 | 53 | 0.090 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 40 | 0.090 |
Why?
|
| Patellofemoral Joint | 1 | 2009 | 16 | 0.090 |
Why?
|
| Tibia | 1 | 2009 | 82 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 6501 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2010 | 176 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2004 | 1204 | 0.090 |
Why?
|
| Adenosine | 1 | 2011 | 225 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 763 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 243 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2011 | 695 | 0.080 |
Why?
|
| Biomarkers | 4 | 2014 | 1718 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 639 | 0.080 |
Why?
|
| Arthrography | 1 | 2007 | 6 | 0.080 |
Why?
|
| Leg Bones | 1 | 2007 | 7 | 0.080 |
Why?
|
| Joint Instability | 1 | 2008 | 81 | 0.080 |
Why?
|
| Streptozocin | 1 | 2007 | 54 | 0.080 |
Why?
|
| Renal Artery Obstruction | 1 | 2007 | 39 | 0.070 |
Why?
|
| Magnetics | 1 | 2007 | 41 | 0.070 |
Why?
|
| Pain | 1 | 2009 | 391 | 0.070 |
Why?
|
| Fiber Optic Technology | 1 | 2007 | 35 | 0.070 |
Why?
|
| Angioplasty, Balloon | 1 | 2007 | 95 | 0.070 |
Why?
|
| Rats, Wistar | 1 | 2007 | 297 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1849 | 0.070 |
Why?
|
| Echo-Planar Imaging | 1 | 2006 | 52 | 0.070 |
Why?
|
| Hepatic Artery | 1 | 2005 | 83 | 0.070 |
Why?
|
| Dogs | 1 | 2006 | 685 | 0.060 |
Why?
|
| Ioxaglic Acid | 2 | 2014 | 7 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 43 | 0.060 |
Why?
|
| Iohexol | 2 | 2014 | 26 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 1047 | 0.060 |
Why?
|
| Myocardium | 2 | 2004 | 529 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1749 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 104 | 0.060 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 32 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2004 | 261 | 0.060 |
Why?
|
| Diaphragm | 1 | 2003 | 50 | 0.060 |
Why?
|
| Respiration | 1 | 2004 | 262 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 238 | 0.060 |
Why?
|
| Motion | 1 | 2002 | 85 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 263 | 0.050 |
Why?
|
| Body Height | 1 | 2002 | 99 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 244 | 0.050 |
Why?
|
| Perfusion | 2 | 2017 | 203 | 0.050 |
Why?
|
| Observer Variation | 1 | 2002 | 602 | 0.050 |
Why?
|
| Creatinine | 1 | 2002 | 338 | 0.050 |
Why?
|
| Weight-Bearing | 2 | 2011 | 61 | 0.050 |
Why?
|
| Body Weight | 1 | 2002 | 459 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2601 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2004 | 710 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2002 | 456 | 0.050 |
Why?
|
| Lung | 2 | 2003 | 1170 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2011 | 8477 | 0.040 |
Why?
|
| Adolescent | 1 | 2011 | 8979 | 0.040 |
Why?
|
| Biomechanical Phenomena | 2 | 2011 | 457 | 0.040 |
Why?
|
| Dinoprost | 1 | 2017 | 26 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 2 | 2011 | 384 | 0.040 |
Why?
|
| Oxytocin | 1 | 2017 | 71 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2002 | 1143 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2007 | 92 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 498 | 0.030 |
Why?
|
| Disease Progression | 2 | 2010 | 1531 | 0.030 |
Why?
|
| Iothalamic Acid | 1 | 2014 | 11 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 275 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 363 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2767 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1924 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3636 | 0.030 |
Why?
|
| Bone Cysts | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cartilage Diseases | 1 | 2010 | 16 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2010 | 54 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 596 | 0.020 |
Why?
|
| Posture | 1 | 2008 | 125 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2007 | 46 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 119 | 0.020 |
Why?
|
| Hip Joint | 1 | 2007 | 55 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 307 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 678 | 0.020 |
Why?
|
| Liver Circulation | 1 | 2005 | 30 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2005 | 47 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 1577 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1801 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 752 | 0.020 |
Why?
|
| Rabbits | 1 | 2005 | 636 | 0.020 |
Why?
|
| Radiography | 1 | 2005 | 813 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 384 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 912 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5417 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 736 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 4212 | 0.010 |
Why?
|